AU3968193A - In vivo peptide therapy - Google Patents

In vivo peptide therapy

Info

Publication number: AU3968193A
Authority: AU; Australia
Prior art keywords: inhibitor; polypeptide; nucleic acid; receptor; natural protein
Prior art date: 1992-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU39681/93A

Other languages

English (en)

Inventor

Mark D Erion

Gary S. Firestein

Harry E. Gruber

Kevin M Mullane

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sicor Inc

Original Assignee

Sicor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-26

Filing date

1993-03-26

Publication date

1993-10-21

1993-03-26 Application filed by Sicor Inc filed Critical Sicor Inc

1993-10-21 Publication of AU3968193A publication Critical patent/AU3968193A/en

Status Abandoned legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 176
238000001727 in vivo Methods 0.000 title claims description 18
238000002560 therapeutic procedure Methods 0.000 title description 3
102000004196 processed proteins & peptides Human genes 0.000 claims description 151
229920001184 polypeptide Polymers 0.000 claims description 130
108090000623 proteins and genes Proteins 0.000 claims description 116
238000000034 method Methods 0.000 claims description 115
239000003112 inhibitor Substances 0.000 claims description 104
102000004169 proteins and genes Human genes 0.000 claims description 81
102000035195 Peptidases Human genes 0.000 claims description 63
108091005804 Peptidases Proteins 0.000 claims description 63
230000002401 inhibitory effect Effects 0.000 claims description 50
108090000783 Renin Proteins 0.000 claims description 49
150000007523 nucleic acids Chemical class 0.000 claims description 43
239000004365 Protease Substances 0.000 claims description 42
108020004707 nucleic acids Proteins 0.000 claims description 40
102000039446 nucleic acids Human genes 0.000 claims description 40
102000005962 receptors Human genes 0.000 claims description 40
108020003175 receptors Proteins 0.000 claims description 40
210000004027 cell Anatomy 0.000 claims description 38
102100028255 Renin Human genes 0.000 claims description 36
102000004190 Enzymes Human genes 0.000 claims description 31
108090000790 Enzymes Proteins 0.000 claims description 31
206010020772 Hypertension Diseases 0.000 claims description 31
230000000694 effects Effects 0.000 claims description 31
229940088598 enzyme Drugs 0.000 claims description 31
238000011282 treatment Methods 0.000 claims description 28
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 24
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 24
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 24
239000000556 agonist Substances 0.000 claims description 24
235000019833 protease Nutrition 0.000 claims description 21
206010003246 arthritis Diseases 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
230000004071 biological effect Effects 0.000 claims description 19
201000010099 disease Diseases 0.000 claims description 19
230000014509 gene expression Effects 0.000 claims description 19
235000019419 proteases Nutrition 0.000 claims description 19
229940088597 hormone Drugs 0.000 claims description 18
239000005556 hormone Substances 0.000 claims description 18
239000013598 vector Substances 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 17
101800001288 Atrial natriuretic factor Proteins 0.000 claims description 15
102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 15
101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 15
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 15
108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 14
230000036772 blood pressure Effects 0.000 claims description 14
239000005557 antagonist Substances 0.000 claims description 12
102000005741 Metalloproteases Human genes 0.000 claims description 11
108010006035 Metalloproteases Proteins 0.000 claims description 11
108030001679 Endothelin-converting enzyme 1 Proteins 0.000 claims description 10
102000048186 Endothelin-converting enzyme 1 Human genes 0.000 claims description 10
230000002860 competitive effect Effects 0.000 claims description 10
210000002889 endothelial cell Anatomy 0.000 claims description 9
230000001177 retroviral effect Effects 0.000 claims description 9
206010019280 Heart failures Diseases 0.000 claims description 8
206010028980 Neoplasm Diseases 0.000 claims description 8
230000015572 biosynthetic process Effects 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 7
108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 6
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 claims description 6
108090000028 Neprilysin Proteins 0.000 claims description 6
102000003729 Neprilysin Human genes 0.000 claims description 6
230000009286 beneficial effect Effects 0.000 claims description 6
230000015556 catabolic process Effects 0.000 claims description 6
208000010125 myocardial infarction Diseases 0.000 claims description 6
230000028327 secretion Effects 0.000 claims description 6
108091007196 stromelysin Proteins 0.000 claims description 6
206010002383 Angina Pectoris Diseases 0.000 claims description 5
102000029816 Collagenase Human genes 0.000 claims description 5
108060005980 Collagenase Proteins 0.000 claims description 5
206010014561 Emphysema Diseases 0.000 claims description 5
108090000190 Thrombin Proteins 0.000 claims description 5
102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims description 5
108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 5
206010047163 Vasospasm Diseases 0.000 claims description 5
239000003146 anticoagulant agent Substances 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
238000006731 degradation reaction Methods 0.000 claims description 5
210000002950 fibroblast Anatomy 0.000 claims description 5
230000009395 genetic defect Effects 0.000 claims description 5
210000003734 kidney Anatomy 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
230000029865 regulation of blood pressure Effects 0.000 claims description 5
229960004072 thrombin Drugs 0.000 claims description 5
239000002753 trypsin inhibitor Substances 0.000 claims description 5
201000001320 Atherosclerosis Diseases 0.000 claims description 4
206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
108090000695 Cytokines Proteins 0.000 claims description 4
102000004127 Cytokines Human genes 0.000 claims description 4
206010061218 Inflammation Diseases 0.000 claims description 4
208000025747 Rheumatic disease Diseases 0.000 claims description 4
208000032594 Vascular Remodeling Diseases 0.000 claims description 4
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 4
102400000015 Vasoactive intestinal peptide Human genes 0.000 claims description 4
229960002424 collagenase Drugs 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
230000007246 mechanism Effects 0.000 claims description 4
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
230000002829 reductive effect Effects 0.000 claims description 4
101710183811 Glia-derived nexin Proteins 0.000 claims description 3
102100033299 Glia-derived nexin Human genes 0.000 claims description 3
208000006011 Stroke Diseases 0.000 claims description 3
208000023589 ischemic disease Diseases 0.000 claims description 3
230000035755 proliferation Effects 0.000 claims description 3
230000002792 vascular Effects 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
108010049003 Fibrinogen Proteins 0.000 claims description 2
102000008946 Fibrinogen Human genes 0.000 claims description 2
208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
206010020880 Hypertrophy Diseases 0.000 claims description 2
101710151321 Melanostatin Proteins 0.000 claims description 2
208000019695 Migraine disease Diseases 0.000 claims description 2
102400000064 Neuropeptide Y Human genes 0.000 claims description 2
208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
206010063897 Renal ischaemia Diseases 0.000 claims description 2
206010039710 Scleroderma Diseases 0.000 claims description 2
208000032109 Transient ischaemic attack Diseases 0.000 claims description 2
108090000631 Trypsin Proteins 0.000 claims description 2
102000004142 Trypsin Human genes 0.000 claims description 2
238000002399 angioplasty Methods 0.000 claims description 2
229940127219 anticoagulant drug Drugs 0.000 claims description 2
230000000747 cardiac effect Effects 0.000 claims description 2
238000006243 chemical reaction Methods 0.000 claims description 2
210000004351 coronary vessel Anatomy 0.000 claims description 2
229940012952 fibrinogen Drugs 0.000 claims description 2
230000004968 inflammatory condition Effects 0.000 claims description 2
230000003993 interaction Effects 0.000 claims description 2
210000004185 liver Anatomy 0.000 claims description 2
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims description 2
239000000813 peptide hormone Substances 0.000 claims description 2
230000001681 protective effect Effects 0.000 claims description 2
238000007634 remodeling Methods 0.000 claims description 2
210000002437 synoviocyte Anatomy 0.000 claims description 2
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
201000010875 transient cerebral ischemia Diseases 0.000 claims description 2
210000004881 tumor cell Anatomy 0.000 claims description 2
230000003313 weakening effect Effects 0.000 claims description 2
102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 claims 4
102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 claims 3
108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 claims 3
108700024394 Exon Proteins 0.000 claims 2
102000007592 Apolipoproteins Human genes 0.000 claims 1
108010071619 Apolipoproteins Proteins 0.000 claims 1
206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
208000006029 Cardiomegaly Diseases 0.000 claims 1
208000001778 Coronary Occlusion Diseases 0.000 claims 1
206010011086 Coronary artery occlusion Diseases 0.000 claims 1
108091092195 Intron Proteins 0.000 claims 1
206010033645 Pancreatitis Diseases 0.000 claims 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
101000925883 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Elastase Proteins 0.000 claims 1
101000584292 Streptomyces cacaoi Mycolysin Proteins 0.000 claims 1
206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
210000002216 heart Anatomy 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
210000002464 muscle smooth vascular Anatomy 0.000 claims 1
108010052605 prostromelysin Proteins 0.000 claims 1
239000012588 trypsin Substances 0.000 claims 1
230000005764 inhibitory process Effects 0.000 description 33
238000001415 gene therapy Methods 0.000 description 13
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 12
102400000345 Angiotensin-2 Human genes 0.000 description 11
101800000733 Angiotensin-2 Proteins 0.000 description 11
229950006323 angiotensin ii Drugs 0.000 description 11
238000004806 packaging method and process Methods 0.000 description 11
230000004952 protein activity Effects 0.000 description 10
150000001413 amino acids Chemical group 0.000 description 9
230000001105 regulatory effect Effects 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
239000012636 effector Substances 0.000 description 8
102000015427 Angiotensins Human genes 0.000 description 7
108010064733 Angiotensins Proteins 0.000 description 7
108050009340 Endothelin Proteins 0.000 description 7
102000002045 Endothelin Human genes 0.000 description 7
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 7
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 6
241000283984 Rodentia Species 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
230000007017 scission Effects 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
241000282412 Homo Species 0.000 description 5
241000219061 Rheum Species 0.000 description 5
230000009471 action Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
238000013461 design Methods 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000012546 transfer Methods 0.000 description 5
102400000344 Angiotensin-1 Human genes 0.000 description 4
101800000734 Angiotensin-1 Proteins 0.000 description 4
102400000967 Bradykinin Human genes 0.000 description 4
101800004538 Bradykinin Proteins 0.000 description 4
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 4
206010023203 Joint destruction Diseases 0.000 description 4
108700005090 Lethal Genes Proteins 0.000 description 4
108010022999 Serine Proteases Proteins 0.000 description 4
102000012479 Serine Proteases Human genes 0.000 description 4
-1 anti-proteinases Proteins 0.000 description 4
230000002785 anti-thrombosis Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
238000012216 screening Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
108050000824 Angiotensin II receptor Proteins 0.000 description 3
102000008873 Angiotensin II receptor Human genes 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
241000700605 Viruses Species 0.000 description 3
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000009510 drug design Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000001631 hypertensive effect Effects 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
210000001503 joint Anatomy 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000017854 proteolysis Effects 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
101150058202 73 gene Proteins 0.000 description 2
108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 2
102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 2
102000004881 Angiotensinogen Human genes 0.000 description 2
108090001067 Angiotensinogen Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
206010010099 Combined immunodeficiency Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
108010007267 Hirudins Proteins 0.000 description 2
102000007625 Hirudins Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108010067902 Peptide Library Proteins 0.000 description 2
101800004937 Protein C Proteins 0.000 description 2
102400000827 Saposin-D Human genes 0.000 description 2
101800001700 Saposin-D Proteins 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000000234 capsid Anatomy 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000003890 endocrine cell Anatomy 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
210000002064 heart cell Anatomy 0.000 description 2
229940006607 hirudin Drugs 0.000 description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
150000002611 lead compounds Chemical class 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
238000000302 molecular modelling Methods 0.000 description 2
230000036963 noncompetitive effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000001566 pro-viral effect Effects 0.000 description 2
229960000856 protein c Drugs 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
230000003331 prothrombotic effect Effects 0.000 description 2
239000002461 renin inhibitor Substances 0.000 description 2
229940086526 renin-inhibitors Drugs 0.000 description 2
238000012552 review Methods 0.000 description 2
210000004739 secretory vesicle Anatomy 0.000 description 2
210000001179 synovial fluid Anatomy 0.000 description 2
210000001258 synovial membrane Anatomy 0.000 description 2
KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
101000666940 Agkistrodon piscivorus piscivorus Disintegrin applaggin Proteins 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
102400000348 Angiotensin-3 Human genes 0.000 description 1
101800000738 Angiotensin-3 Proteins 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
101800001415 Bri23 peptide Proteins 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
101800000655 C-terminal peptide Proteins 0.000 description 1
102400000113 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
108010024212 E-Selectin Proteins 0.000 description 1
102100023471 E-selectin Human genes 0.000 description 1
229940122858 Elastase inhibitor Drugs 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
240000006570 Euonymus japonicus Species 0.000 description 1
235000016796 Euonymus japonicus Nutrition 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
101710089384 Extracellular protease Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
101000579218 Homo sapiens Renin Proteins 0.000 description 1
101100153329 Homo sapiens TIMP1 gene Proteins 0.000 description 1
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
102000039996 IL-1 family Human genes 0.000 description 1
108091069196 IL-1 family Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010023198 Joint ankylosis Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
HSQGMTRYSIHDAC-BQBZGAKWSA-N Leu-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(O)=O HSQGMTRYSIHDAC-BQBZGAKWSA-N 0.000 description 1
102000011965 Lipoprotein Receptors Human genes 0.000 description 1
108010061306 Lipoprotein Receptors Proteins 0.000 description 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
108010050808 Procollagen Proteins 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038563 Reocclusion Diseases 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
108010045759 Teprotide Proteins 0.000 description 1
UUUHXMGGBIUAPW-CSCXCSGISA-N Teprotide Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCC(=O)N1 UUUHXMGGBIUAPW-CSCXCSGISA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
101150030413 Timp gene Proteins 0.000 description 1
MQVGIFJSFFVGFW-XEGUGMAKSA-N Trp-Ala-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MQVGIFJSFFVGFW-XEGUGMAKSA-N 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
241000271897 Viperidae Species 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
239000002416 angiotensin derivative Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
108010058865 angiotensinase Proteins 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001407 anti-thrombic effect Effects 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
210000000544 articulatio talocruralis Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
208000005980 beta thalassemia Diseases 0.000 description 1
108010055460 bivalirudin Proteins 0.000 description 1
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
229960001500 bivalirudin Drugs 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000004074 complement inhibitor Substances 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000012937 correction Methods 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000002224 dissection Methods 0.000 description 1
108010025752 echistatin Proteins 0.000 description 1
239000003602 elastase inhibitor Substances 0.000 description 1
239000002308 endothelin receptor antagonist Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
230000003325 follicular Effects 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000010952 in-situ formation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
210000005067 joint tissue Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
108010059557 kistrin Proteins 0.000 description 1
108010071185 leucyl-alanine Proteins 0.000 description 1
238000011694 lewis rat Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008035 nerve activity Effects 0.000 description 1
230000003227 neuromodulating effect Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
108010024607 phenylalanylalanine Proteins 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108010067999 preproalbumin Proteins 0.000 description 1
108010066381 preproinsulin Proteins 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012508 resin bead Substances 0.000 description 1
ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 description 1
230000009962 secretion pathway Effects 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000011895 specific detection Methods 0.000 description 1
108010003641 statine renin inhibitory peptide Proteins 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
210000005222 synovial tissue Anatomy 0.000 description 1
229950010186 teprotide Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000005945 translocation Effects 0.000 description 1
108010060000 trigramin Proteins 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000009790 vascular invasion Effects 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000002435 venom Substances 0.000 description 1
210000001048 venom Anatomy 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/553—Renin inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AU39681/93A 1992-03-26 1993-03-26 In vivo peptide therapy Abandoned AU3968193A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US858128		1977-12-06
US85812892A	1992-03-26	1992-03-26
PCT/US1993/002819 WO1993018794A1 (fr)	1992-03-26	1993-03-26	Therapie in vivo recourant a des peptides

Publications (1)

Publication Number	Publication Date
AU3968193A true AU3968193A (en)	1993-10-21

Family

ID=25327555

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU39681/93A Abandoned AU3968193A (en)	1992-03-26	1993-03-26	In vivo peptide therapy

Country Status (3)

Country	Link
EP (1)	EP0670737A4 (fr)
AU (1)	AU3968193A (fr)
WO (1)	WO1993018794A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206017A (en) *	1986-06-03	1993-04-27	Incyte Pharmaceuticals, Inc.	Use of protease nexin-I as an antiinflammatory
JPH10508187A (ja) *	1994-08-26	1998-08-18	ノバルティス・アクチェンゲゼルシャフト	移植および炎症または血栓症のための遺伝子療法
EP0802801A2 (fr) *	1994-12-30	1997-10-29	Chiron Corporation	Procedes et compostions de traitement de tumeurs solides in vivo
US6030975A (en) *	1997-03-14	2000-02-29	Basf Aktiengesellschaft	Carboxylic acid derivatives, their preparation and use in treating cancer
HU0900792D0 (en)	1997-10-17	2010-03-01	Ark Therapeutics Ltd	Use of renin-angiotensin inhibitors
AU3731400A (en)	1999-03-05	2000-09-21	Trustees Of University Technology Corporation, The	Methods and compositions useful in inhibiting apoptosis
US6849605B1 (en)	1999-03-05	2005-02-01	The Trustees Of University Technology Corporation	Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU2001231009A1 (en)	2000-01-21	2001-07-31	Beth Israel Deaconess Medical Center	Use of pro-apoptotic factors in treatment of atherosclerosis
DE10138550A1 (de) *	2001-08-06	2003-02-20	Wolfgang E Berdel	Verwendung von TIMP-1 als Immunsuppressivum
CA2536918A1 (fr)	2003-08-26	2005-03-03	Leland Shapiro	Compositions et procedes pour molecules de fusion fc de l'alpha-1 antitrypsine
WO2006094070A2 (fr)	2005-03-01	2006-09-08	Stratatech Corporation	Substituts de peau humaine exprimant des polypeptides exogenes
FR2953723B1 (fr) *	2009-12-11	2012-02-24	Scarcell Therapeutics	Composition pharmaceutique destinee au traitement des pathologies orthopediques
EP2723370A4 (fr)	2011-06-24	2015-06-03	Univ Colorado Regents	Compositions, procédés et utilisations de molécules de fusion de l'alpha-1 antitrypsine
US10478508B2 (en)	2012-01-10	2019-11-19	The Regents Of The University Of Colorado, A Body Corporate	Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4497796A (en) *	1980-03-26	1985-02-05	The Regents Of The University Of California	Gene transfer in intact mammals
US5280106A (en) *	1988-05-20	1994-01-18	Liotta Lance A	Matrix metalloproteinase peptides: role in diagnosis and therapy
WO1989011657A1 (fr) *	1988-05-25	1989-11-30	Cambridge Research Biochemicals Limited	Analyse pour detecter l'expression d'oncogenes
GB8822483D0 (en) *	1988-09-24	1988-10-26	Medical Res Council	Developments relating to mas oncogene
DE69033982T2 (de) *	1989-03-21	2002-10-24	The United States Of America, Represented By The Secretary	Matrizenmetalloproteinase-inhibitor-peptide
US7769623B2 (en) *	2002-12-17	2010-08-03	International Business Machines Corporation	Method and system for conducting online marketing research in a controlled manner

1993
- 1993-03-26 EP EP93909173A patent/EP0670737A4/fr not_active Withdrawn
- 1993-03-26 WO PCT/US1993/002819 patent/WO1993018794A1/fr not_active Ceased
- 1993-03-26 AU AU39681/93A patent/AU3968193A/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0670737A4 (fr)	1996-05-29
WO1993018794A1 (fr)	1993-09-30
EP0670737A1 (fr)	1995-09-13

Publication	Publication Date	Title
Husain	1993	The chymase-angiotensin system in humans
US5550213A (en)	1996-08-27	Inhibitors of urokinase plasminogen activator
US7019123B2 (en)	2006-03-28	Human bikunin
US5318899A (en)	1994-06-07	Platelet aggregation inhibitors
KR100278036B1 (ko)	2001-01-15	사람 쿠니즈형 프로테아제 저해제 변이체
US5686567A (en)	1997-11-11	Platelet aggregation inhibitors
AU3968193A (en)	1993-10-21	In vivo peptide therapy
US5639726A (en)	1997-06-17	Peptide mediated enhancement of thrombolysis methods and compositions
Stewart	2004	Bradykinin antagonists: discovery and development
JPH09509838A (ja)	1997-10-07	クニッツドメイン拮抗剤蛋白質
CA2163741A1 (fr)	1994-12-08	Peptides, inhibiteurs de l'activite du recepteur de l'urokinase
US20200222516A1 (en)	2020-07-16	Compositions and Methods for Modulating Cardiac Conditions
US5491129A (en)	1996-02-13	Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
Scharpe et al.	1991	Proteases and their inhibitors: today and tomorrow
EP0419099A1 (fr)	1991-03-27	Protéines ayant des propriétés anticoagulantes
EP0616614A1 (fr)	1994-09-28	Compositions et procedes d'inhibition de l'elastase
JP3270760B2 (ja)	2002-04-02	フリンによるタンパクの微生物的生産方法及びその生産のための細胞
CN101372512A (zh)	2009-02-25	一类抗凝血多肽及其用途
HUT74873A (en)	1997-02-28	Factor vii-derived peptides
Markwardt	1991	The comeback of hirudin as an antithrombotic agent
CN102268070B (zh)	2012-11-28	基质金属蛋白酶-9多肽抑制剂2及其应用
US7498299B2 (en)	2009-03-03	Procollagen (III) propeptides and related substances for treating fibrotic diseases
CA2134237A1 (fr)	1993-09-30	Therapie peptidique in vivo
US20040127396A1 (en)	2004-07-01	Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases
Chao et al.	1997	Kallistatin in Blood Pressure Regulation: Transgenic and Somatic Gene Delivery Studies